Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology.
At the this year’s edition of the TOP 100 Swiss Startup Award, where Switzerland’s best startups are celebrated, Araris ranks TOP11! What a great success for Araris, after positions 13 in 2020 and 95 in 2019.
We congratulate Philipp Spycher (CEO) and his team for this great achievement!